ストックスクリーナーアプリを入手
2.585
3.90%
-0.105
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
Around the Helix: Cell and Gene Therapy Company Updates – August 20, 2025 - CGTLive®
Iovance Biotherapeutics Gains Health Canada Approval - MSN
Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Potential Securities Fraud Allegations - 28/22 News
Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada - CGTLive®
Unexpected Surge: Analyzing Iovance’s Performance - StocksToTrade
Why Iovance Biotherapeutics Stock Was Climbing Today - Mitrade
Why Iovance Biotherapeutics Stock Was Climbing Today - The Motley Fool
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ - Stocktwits
Iovance Stock Soars 21.2% on Amtagvi Approval - AInvest
Iovance gets conditional Health Canada approval for Amtagvi - MSN
Health Canada approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com India
Iovance Says Amtagvi Gets Health Canada Clearance for Advanced Melanoma - MarketScreener
Health Canada approves Iovance’s Amtagvi for advanced melanoma - Investing.com
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - The Manila Times
Iovance Biotherapeutics Receives Health Canada Approval for Amtagvi® T Cell Therapy for Advanced Melanoma - Quiver Quantitative
Iovance's Amtagvi receives Health Canada approval for advanced melanoma - MarketScreener
First-Ever T Cell Therapy for Solid Tumors: Iovance's Amtagvi Gets Historic Canada Approval - Stock Titan
Wells Fargo Lowers Price Target for Iovance Biotherapeutics (IOVA) Amid Mixed Q2 Results: Is Amtagvi's Growth Enough to Justify the Downgrade? - AInvest
Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth - Yahoo Finance
Is Iovance Biotherapeutics Inc. a momentum stock2025 Stock Rankings & Safe Capital Growth Plans - thegnnews.com
Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - MSN
Iovance Biotherapeutics shares rise 2.04% premarket as private investment in oncology ventures surges. - AInvest
Iovance Biotherapeutics’ SWOT analysis: navigating challenges in cancer immunotherapy stock - Investing.com
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN
Iovance Biotherapeutics shares rise 3.27% intraday as private investment in oncology ventures surges. - AInvest
Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance
Iovance Biotherapeutics' Earnings Call Highlights Growth, Revenue Up 22% to $60M - AInvest
Iovance Biotherapeutics’ Earnings Call Highlights Growth - TipRanks
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve
Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade
Iovance Biotherapeutics Surges on Promising Study Outcomes - timothysykes.com
AI Tools Suggest Iovance Biotherapeutics Inc. May Outperform This WeekBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈
Published on: 2025-08-12 06:23:53 - beatles.ru
Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛
Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest
Iovance Biotherapeutics Q2 Revenue Misses Estimates, Shares Plummet - AInvest
Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade
Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser
Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
Iovance falls after missing Q2 expectation - MSN
Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha
Iovance to Cut Staff by 20% Amid Slow Sales Start for Amtagvi Cell Therapy - AInvest
Iovance Biotherapeutics Reports Q2 Loss, Stock Down on EMA Filing Withdrawal for Amtagvi - AInvest
Goldman Sachs Downgrades Iovance Biotherapeutics Amid Lawsuit Turmoil - StocksToTrade
Iovance: Wells Fargo Maintains Overweight Rating, PT Down to $14 - AInvest
Iovance Shares Dip as CFO Changes and Legal Troubles Mount - timothysykes.com
Iovance Bio updates on Amtagvi - The Pharma Letter
Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade
Is Iovance’s Stock Plummet A Buying Chance? - timothysykes.com
Chardan Capital Maintains Buy Rating on Iovance with PT Down to $20. - AInvest
Lacklustre Amtagvi launch forces Iovance to cut 19% of staff - FirstWord Pharma
Iovance Biotherapeutics: Q2 Earnings Snapshot - Connecticut Post
1.05%
大文字化:
|
ボリューム (24 時間):